A5049595415- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- RNA Interference and Gene Delivery
- Advanced Drug Delivery Systems
- Advancements in Transdermal Drug Delivery
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Viral gastroenteritis research and epidemiology
- COVID-19 Impact on Reproduction
- Curcumin's Biomedical Applications
- Toxin Mechanisms and Immunotoxins
- Surfactants and Colloidal Systems
- Neonatal Respiratory Health Research
- Pneumonia and Respiratory Infections
- Biosensors and Analytical Detection
- Process Optimization and Integration
- Cancer, Hypoxia, and Metabolism
- vaccines and immunoinformatics approaches
- High Altitude and Hypoxia
- Pharmacological Receptor Mechanisms and Effects
- Nicotinic Acetylcholine Receptors Study
- Respiratory viral infections research
- Dendrimers and Hyperbranched Polymers
Pontificia Universidad Católica de Chile
2008-2024
Millennium Institute on Immunology and Immunotherapy
2020-2021
Center for Research in Molecular Medicine and Chronic Diseases
2012-2019
Universidade de Santiago de Compostela
2012-2019
University of Notre Dame
2019
The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports results obtained for healthy Chilean adults aged ≥18 years in phase 3 clinical trial.Volunteers randomly received doses or placebo, separated by weeks. A total 434 volunteers were enrolled, 397 18-59 37 ≥60 years. Solicited unsolicited adverse...
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible of current pandemic ongoing all around world. Since its discovery in 2019, several circulating variants have emerged and some them are associated with increased infections death rate. Despite genetic differences among these variants, vaccines approved for human use shown a good immunogenic protective response against them. In Chile, over 70% vaccinated population immunized CoronaVac, an...
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines currently approved for emergency use in population, while ongoing studies continue provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good immunogenicity profile as seen phase 1, 2, 3 clinical trials world, effectiveness of 65.9% symptomatic cases. Although vaccination...
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 4 weeks after two doses CoronaVac; these were significantly reduced at 6 to 8 months doses. Here, we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOCs), Delta Omicron, in adults participating phase III clinical trial Chile. Volunteers immunized with...
BackgroundRespiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants represents a significant economic burden public health. The development of safe, effective, affordable vaccine priority the WHO.MethodsWe conducted double-blinded, escalating-dose phase 1 clinical trial healthy males aged 18-50 years to evaluate safety, tolerability, immunogenicity recombinant Mycobacterium bovis BCG expressing nucleoprotein RSV (rBCG-N-hRSV). Once...
The use of biomaterials and nanosystems in antigen delivery has played a major role the development novel vaccine formulations last few decades. In an effort to gain deeper understanding interactions between these systems immunocompetent cells, we describe here systematic vitro vivo study on three types polymeric nanocapsules (NCs). These carriers, which contained Protamine (PR), Polyarginine (PARG) or Chitosan (CS) external shell, their corresponding nanoemulsion were prepared main...
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response pediatric population are scarce. The inactivated vaccine CoronaVac has shown to be safe and immunogenic a phase 1/2 trial cohort China. Here, we report interim safety immunogenicity results of 3 for healthy children adolescents Chile. Participants 17 years old received two doses 4-week interval until 31 December 2021....
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
To develop a new core-shell type (nanocapsules) adjuvant system composed of squalene and polyglucosamine (PG) to evaluate its immunostimulant capacity.The defined PG nanocapsules exhibited the capacity efficiently associate selected antigens (recombinant hepatitis B surface antigen hemagglutinin influenza virus) onto their polymeric (70-75%), imiquimod within oily core. The resulting nanovaccines, with particle size 200-250 nm positive zeta-potential (∼+60 mV), were able significantly...
Transcutaneous vaccination has several advantages including having a noninvasive route and needle-free administration; nonetheless developing an effective transdermal formulation not been easy task because skin physiology, particularly the stratum corneum, does allow antigen penetration. Size is crucial parameter for successful active molecule administration through skin. Here we report new core-shell structure rationally developed transcutaneous delivery. The resulting multifunctional...
One of the main challenges in development vaccine has been to improve their stability at room temperature and eliminate limitations associated with cold chain storage. In this paper, we describe optimization thermostable nanocarriers consisting an oily core immunostimulating activity, containing squalene or α tocopherol surrounded by a protamine shell. The results showed that these nanocapsules can efficiently associate recombinant hepatitis B surface antigen (rHBsAg) without compromising...
Vaccination faces many challenges nowadays, and among them the use of adjuvant molecules needle-free administration are some most demanding. The combination transcutaneous vaccination nanomedicine through a rationally designed new-formulation could be solution to this problem. This study focuses on rational design. For purpose, new hyaluronic acid nanocapsules (HA-NCs) have been developed. formulation has an oily nucleus with immunoadjuvant properties (due α tocopherol) shell made (HA)...
Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe cases. We investigate non-inferiority of two immunization schedules CoronaVac® in a trial healthy adults. A total 2302 adults were enrolled at 8 centers Chile randomly assigned vaccination schedules, receiving doses with either 14 or 28 days between each. The primary efficacy endpoints solicited adverse events...
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials China, Brazil, Indonesia, Turkey, Chile. Methods: This study randomized, multicenter, controlled phase 3 trial healthy Chilean adults aged ≥18 years. Volunteers received two doses...
Novel protamine-based nanosystems have been studied for cyclosporine-A (CsA) skin delivery. Core-shell structure systems developed to this end. These vehicles particles sizes of 200-300 nm, a low polydispersity index and zeta potential which varies between -16 mV +35 mV. The resulting four efficiently encapsulated CsA in their oily nucleus (60-80%) released drug controlled manner. formulations shown high stability aqueous suspension storage conditions at 4 °C (for least 21 months) acetate...